Genetic variants of the NOTCH3 gene in the elderly and magnetic resonance imaging correlates of age-related cerebral small vessel disease

Brain

Volumn 134, Issue 11, 2011, Pages 3384-3397

  Schmidt, Helena ^a   Zeginigg, Marion ^a   Wiltgen, Marco ^a   Freudenberger, Paul ^a   Petrovic, Katja ^a   Cavalieri, Margherita ^a   Gider, Pierre ^a   Enzinger, Christian ^a   Fornage, Myriam ^b,c   Debette, Stephanie ^d   Rotter, Jerome I ^e   Ikram, Mohammad A ^f,g   Launer, Lenore J ^h   Schmidt, Reinhold ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF TEXAS SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f ERASMUS MEDICAL CENTER   (Netherlands)

^g Netherlands Consortium for Healthy Ageing   (Netherlands)

^h NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

ageing; cerebral small vessel disease; genetics; MRI; NOTCH3

Indexed keywords

CYSTEINE; NOTCH2 RECEPTOR;

3' UNTRANSLATED REGION; ADULT; AGED; ARTERIOGRAPHY; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BRAIN DAMAGE; CADASIL; CEREBRAL SMALL VESSEL DISEASE; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; EXON; EXTERNAL CAPSULE; GENE SEQUENCE; GENETIC VARIABILITY; HISTOPATHOLOGY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN STRUCTURE; RADIODIAGNOSIS; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WHITE MATTER;

EID: 81055147238     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awr252     Document Type: Article

References (52)

1. Adib-Samii P, Brice G, Martin RJ, Markus HS. Clinical spectrum of CADASIL and the effect of cardiovascular risk factors on phenotype: study in 200 consecutively recruited individuals. Stroke 2010; 41: 630-4.
2. Arboleda-Velasquez JF, Manent J, Lee JH, Tikka S, Ospina C, Vanderburg CR, et al. Hypomorphic Notch 3 alleles link Notch signaling to ischemic cerebral small-vessel disease. Proc Natl Acad Sci USA 2011; 108: E128-35.
3. Arboleda-Velasquez JF, Zhou Z, Shin HK, Louvi A, Kim HH, Savitz SI, et al. Linking Notch signaling to ischemic stroke. Proc Natl Acad Sci USA 2008; 105: 4856-61. (Pubitemid 351753836)
4. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. [Review]. Science 1999; 284: 770-6. (Pubitemid 29291335)
5. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D'Agostino RB, et al. Genetic variation in white matter hyperintensity volume in the Framingham Study. Stroke 2004; 35: 1609-13. (Pubitemid 38823634)
6. Ayata C. CADASIL: experimental insights from animal models. [Review]. Stroke 2010; 41: S129-34.
7. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5. (Pubitemid 40202029)
8. Berleant D, White M, Pierce E, Tudoreanu E, Boeszoermenyi A, Shtridelman Y, et al. The genetic code-more than just a Table. [Review]. Cell Biochem Biophys 2009; 55: 107-16.
9. Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to meta-analysis. West Sussex, UK: John Wiley & Sons, Ltd; 2009.
10. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology 1994; 44: 1246-52. (Pubitemid 24232223)
11. Carmelli D, DeCarli C, Swan GE, Jack LM, Reed T, Wolf PA, et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998; 29: 1177-81. (Pubitemid 28265474)
12. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. [Review]. Lancet Neurol 2009; 8: 643-53.
13. Chabriat H, Vahedi K, Iba-Zizen MT, Joutel A, Nibbio A, Nagy TG, et al. Clinical spectrum of CADASIL: a study of 7 families. Cerebral autosomal dominant arteriopathy with subcortical infarcts and leu-koencephalopathy. Lancet 1995; 346: 934-9.
14. Desmond DW, Moroney JT, Lynch T, Chan S, Chin SS, Mohr JP. The natural history of CADASIL: a pooled analysis of previously published cases. Stroke 1999; 30: 1230-3. (Pubitemid 29259179)
15. Dichgans M, Mayer M, Uttner I, Brüning R, Müller-Höcker J, Rungger G, et al. The phenotypic spectrum of CADASIL: clinical findings in 102 cases. Ann Neurol 1998; 44: 31-9.
16. Domenga V, Fardoux P, Lacombe P, Monet M, Maciazek J, Krebs LT, et al. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004; 18: 2730-5. (Pubitemid 39507766)
17. Donahue CP, Kosik KS. Distribution pattern of Notch3 mutations suggests a gain-of-function mechanism for CADASIL. Genomics 2004; 83: 59-65. (Pubitemid 37518260)
18. Folstein M, Folstein S, McHugh P. Mini Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
19. Fornage M, Debette S, Bis JC, Schmidt H, Ikram AM, Dufouil C, et al. A locus on chromosome 17q25 influences burden of MRI-defined cerebral white matter hyperintensities in individuals of European descent. Ann Neurol 2011; 69: 928-39.
20. Fouillade C, Chabriat H, Riant F, Mine M, Arnoud M, Magy L, et al. Activating NOTCH3 mutation in a patient with small-vessel-disease of the brain. Hum Mutat 2008; 29: 452-9.
21. Gómez-Angelats E, de La Sierra A, Sierra C, Parati G, Mancia G, Coca A. Blood pressure variability and silent cerebral damage in essential hypertension. Am J Hypertens, 2004, 17, 696-700. (Pubitemid 39091550)
22. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modelling. Electrophoresis 1997; 18: 2714-23. (Pubitemid 28059943)
23. Inzitari D, Pracucci G, Poggesi A, Carlucci G, Barkhof F, Chabriat H, et al. LADIS Study Group. Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. BMJ 2009; 339: b2477.
24. Janke W, Debus G. Die Eigenschaftswoerterliste (EWL). Handanweisung. Hogrefe: Goettingen; 1978.
25. Joutel A, Corpechot C, Ducros A, Vahedi K, Chabriat H, Mouton P, et al. Notch3 mutations in CADASIL, a hereditary adult-onset condition causing stroke and dementia. Nature 1996; 383: 707-10. (Pubitemid 26360644)
26. Joutel A, Monet-Leprêtre M, Gosele C, Baron-Menguy C, Hammes A, Schmidt S, et al. Cerebrovascular dysfunction and microcirculation rarefaction precede white matter lesions in a mouse genetic model of cerebral ischemic small vessel disease. J Clin Invest 2010; 120: 433-45.
27. Kelley LA, Sternberg MJ. Protein structure prediction on the Web: a case study using the Phyre server. Nat Protoc 2009; 4: 363-71.
28. Kim Y, Choi EJ, Choi CG, Kim G, Choi JH, Yoo HW, et al. Characteristics of CADASIL in Korea: a novel cysteine-sparing Notch3 mutation. Neurology 2006; 66: 1511-6. (Pubitemid 43958545)
29. Launer LJ, Berger K, Breteler MM, Dufouil C, Fuhrer R, Giampaoli S, et al. Regional variability in the prevalence of cerebral white matter lesions: an MRI study in 9 European countries (CASCADE). Neuroepidemiology 2006; 26: 23-9. (Pubitemid 41797934)
30. Li Z, Yu H, Zhuang W, Mukamel S. Geometry and excitation energy fluctuations of NMA in aqueous solution with CHARMM, AMBER, OPLS, and GROMOS force fields: implications for protein ultraviolet spectra simulation. Chem Phys Lett 2008; 452: 78-83.
31. Longstreth WT Jr, Arnold AM, Beauchamp NJ Jr, Manolio TA, Lefkowitz D, Jungreis C, et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study. Stroke 2005; 36: 56-61. (Pubitemid 40054175)
32. Markus HS, Martin RJ, Simpson MA, Dong YB, Ali N, Crosby AH, et al. Diagnostic strategies in CADASIL. Neurology 2002; 59: 1134-8. (Pubitemid 35192381)
33. Mizuno T, Muranishi M, Torugun T, Tango H, Nagakane Y, Kudeken T, et al. Two Japanese CADASIL families exhibiting Notch3 mutation R75P not involving cysteine residue. Inter Med 2008; 47: 2067-72.
34. Morrow D, Guha S, Sweeney C, Birney Y, Walshe T, O'Brien C, et al. Notch and vascular smooth muscle cell phenotype. [Review]. Circ Res 2008; 103, 1370-82.
35. Morrow D, Sweeney C, Birney YA, Cummins PM, Walls D, Redmond EM, et al. Cyclic strain inhibits Notch receptor signaling in vascular smooth muscle cells in vitro. Circ Res 2005; 96: 567-75. (Pubitemid 40463466)
36. O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al. Vascular cognitive impairment. [Review]. Lancet Neurol 2003; 2: 89-98.
37. Pantoni L, Garcia JH, Gutierrez JA. Cerebral white matter is highly vulnerable to ischemia. Stroke 1996; 27: 1641-7. (Pubitemid 26295918)
38. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol 2010; 9: 689-701.
39. Psaty BM, O'Donnell CJ, Gudnason V, Lunetta KL, Folsom AR, Rotter JI, et al. Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium: Design of prospective meta-analyses of genome-wide association studies from five cohorts. Circ Cardiovasc Genet 2009; 2: 73-80.
40. Reyes S, Viswanathan A, Godin O, Dufouil C, Benisty S, Hernandez K, et al. Apathy: a major symptom in CADASIL. Neurology 2009; 72: 905-10.
41. Rosano C, Brach J, Longstreth WT Jr, Newman AB. Quantitative measures of gait characteristics indicate prevalence of underlying subclinical structural brain abnormalities in high-functioning older adults. Neuroepidemiology 2006; 26: 52-60. (Pubitemid 41797938)
42. Schmidt H, Fazekas F, Kostner GM, van Duijn CM, Schmidt R. Angiotensinogen gene promoter haplotype and microangiopathy-related cerebral damage: results of the Austrian Stroke Prevention Study. Stroke 2001; 32: 405-12. (Pubitemid 32155226)
43. Schmidt H, Aulchenko YS, Schweighofer N, Schmidt R, Frank S, Kostner GM, et al. Angiotensinogen promoter B-haplotype associated with cerebral small vessel disease enhances basal transcriptional activity. Stroke 2004; 35: 2592-7. (Pubitemid 39458423)
44. Schmidt R, Fazekas F, Kapeller P, Schmidt H, Hartung HP. MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study. Neurology 1999; 53: 132-9. (Pubitemid 29329661)
45. Schmidt R, Lechner H, Fazekas F, Niederkorn K, Reinhart B, Grieshofer P, et al. Assessment of cerebrovascular risk profiles in healthy persons: definition of research goals and the Austrian Stroke Prevention Study (ASPS). Neuroepidemiology 1994; 13: 308-13. (Pubitemid 24263566)
46. Schmidt R, Ropele S, Enzinger C, Petrovic K, Smith S, Schmidt H, et al. White matter lesion progression, brain atrophy, and cognitive decline: the Austrian stroke prevention study. Ann Neurol 2005; 58: 610-6. (Pubitemid 41377225)
47. Schmidt R, Petrovic K, Ropele S, Enzinger C, Fazekas F. Progression of leukoaraiosis and cognition. Stroke 2007; 38: 2619-25. (Pubitemid 47329648)
48. Srikanth V, Beare R, Blizzard L, Phan T, Stapleton J, Chen J, et al. Cerebral white matter lesions, gait, and the risk of incident falls: a prospective population-based study. Stroke 2009; 40: 175-80.
49. Sussman JL, Abola EE, Lin D, Jiang J, Manning NO, Prilusky J. The protein data bank. Bridging the gap between the sequence and 3D structure world. Genetica 1999; 106: 149-58. (Pubitemid 30049243)
50. van den Boom R, Lesnik Oberstein SA, Ferrari MD, Haan J, van Buchem MA. Cerebral autosomal dominant arteriopathy with subcor-tical infarcts and leukoencephalopathy: MR imaging findings at different ages-3rd-6th decades. Radiology 2003; 229: 683-90. (Pubitemid 37467569)
51. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003b; 348: 1215-22. (Pubitemid 36359297)
52. Wang T, Baron M, Trump D. An overview of Notch3 function in vascular smooth muscle cells. [Review]. Prog Biophys Mol Biol 2008; 96: 499-509. (Pubitemid 351635621)